The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

Findings from a 3-year analysis demonstrated that among patients treated with tirzepatide, 98.8% remained diabetes free.

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

The 731-patient SUMMIT study showed that patients treated with tirzepatide also experienced improvements in heart failure ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is currently approved by the Food and Drug Administration for type 2 diabetes under the ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became ...

A new study has found that Mounjaro may not only be good at treating diabetes, but could actually help prevent the disease.

Gaffigan admitted to having trepidation to use the medication, a brand name for tirzepatide, after tipping the scales at 270 ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, ...